Breakfast Sessions
About the Breakfast Sessions
Breakfast sessions are available for all delegates to attend (excluding exhibitors) and spaces are limited and strictly on a first come first serve basis. A stand-up buffet breakfast will be provided and available 30 minutes before the sessions commence.
Please click on the links below for more information on the breakfast topics. In order to attend the breakfast sessions, you will be required to indicate your attendance as part of your registration form.
Wednesday 19 June |
Thursday 20 June |
Friday 21 June |
Gilead |
Lilly |
Merck |
| Optimising Patient Management in mTNBC with Trodelvy | VERZENIO in high-risk* HR+, HER2- early breast cancer | ONCADERM Education: Identify and manage cutaneous reactions in patients being treated with EGFR inhibitors. |
Slater and Gordon Lawyers |
AstraZeneca |
Astellas |
| Dust and Occupational Cancers | Innovative Models of Care and Business Strategies for Tomorrow's Healthcare | Changing management of GU cancers: A practical guide |
Wednesday 19 June
Breakfast Session 1: Optimising Patient Management in mTNBC with Trodelvy
Time: 0800 - 0900 - A stand-up buffet breakfast will be provided and available 30 minutes before the sessions commence (7.30am - 8.00am). This will be served outside the meeting room.
Description:
Join us for an interactive learning journey.
Explore optimising patient care with expert nurse facilitators, navigating the patient pathway and recommended supportive care for metastatic triple negative breast cancer patients undergoing Trodelvy treatment in the second-line setting.
Chairperson: Justin Hargreaves, NP
Facilitators:
- Nurse Practitioners: Marisa Stevens, Gillian Kruss, Jenny Gilchrist, Michael Fitzgerald, Michael Cooney, Gillian Blanchard
- Nurse Practitioner Candidate: Katie Cao
- McGrath Breast Care Nurse: Samantha Moules
Breakfast Session 2: Dust and Occupational Cancers
Time: 0830 - 0930 - A stand-up buffet breakfast will be provided and available 30 minutes before the sessions commence (8.00am - 8.30am). This will be served outside the meeting room.
Presenters:
- Sean Sweeney – Senior Associate, Asbestos and Dust Diseases
- Raelene Lingam – Legal Counsel, Asbestos and Dust Diseases
- Tracy Madden – Senior Legal Counsel, Asbestos and Dust Diseases
Description:
Overviews of occupational cancers including:
- Mesothelioma and asbestos-related cancer
- Silicosis and silica-related lung cancer
- Other cancers, including bladder cancer, melanoma, Leukemia, pancreatic cancer, nasal cancer, non-Hodgkin’s lymphoma
- Types of carcinogens and ‘at-risk’ industries, including firefighters, painters, welders, those exposed to engine exhaust, mould or pesticides
- Entitlements to common law and statutory compensation and the general process of a claim
- Terminal illness and total and permanent disability entitlements
- Case studies
- Future predictions based on current research
Thursday 20 June
Breakfast Session 1: VERZENIO in high-risk* HR+, HER2- early breast cancer: Explaining the role of Verzenio to Patients
Time: 0730 - 0830 - A stand-up buffet breakfast will be provided and available 30 minutes before the sessions commence (7.00am - 7.30am). This will be served outside the meeting room.
Presenters: Associate Professor Liz Caldon and Cath Griffiths
Description:
Join us for an educational symposium where Associate Prof Liz Caldon, Garvan Institute of Medical Research will explore the mode of action for Verzenio and the role it plays in combination with ET in high-risk HR+, HER2- EBC patients. Cath Griffiths, Early Breast Cancer Nurse at Breast Cancer Research centre, Perth will share her experience in successfully introducing, monitoring, and managing such patients whilst on Verzenio + ET for adjuvant treatment.
EBC: early breast cancer, ET: Endocrine Therapy HER2-: human epidermal growth factor receptor 2 negative, HR+: hormone receptor positive
*High-risk EBC was defined as patients who had 4 or more positive nodes, or 1–3 positive nodes with either grade 3 disease, tumour size ≥5 cm, or a Ki-67 index ≥20%.1–3
References: 1. VERZENIO Approved Product Information. 2. Johnston SR et al. J Clin Oncol. 2020;38(34):3987–98. 3. Fasching P et al. Breast Cancer Res Treat.
2019;175(3):617–25. PP-AL-AU-0723 Apr 2024
Breakfast Session 2: Empowering Nursing Excellence: Innovative Models of Care and Business Strategies for Tomorrow's Healthcare
Time: 0730 - 0830 - A stand-up buffet breakfast will be provided and available 30 minutes before the sessions commence (7.00am - 7.30am). This will be served outside the meeting room.
Presenters:
Sara McLaughlin-Barrett, RN, Head of Patient Affairs, MedWise Consulting, Melbourne
Rebecca Kimberley, Nurse Practitioner, Princess Alexandra Hospital, Brisbane
Description:
Please join us for the AstraZeneca-sponsored breakfast symposium at the Cancer Nurses Society of Australia (CNSA) Annual Congress. The inspiring program has been designed to empower you, as nurses, to establish models of care, have confidence with business cases and to secure funding for nurse-led clinics.
Please click here for more information about this session.
Friday 21 June
Title: ONCADERM Education: Identify and manage cutaneous reactions in patients being treated with EGFR inhibitors.
Time: 0730 - 0830 - A stand-up buffet breakfast will be provided and available 30 minutes before the sessions commence (7.00am - 7.30am). This will be served outside the meeting room.
Presenter: Professor Pablo Fernández-Peñas
Description:
The ONCADERM program aims to provide structured education to assist with the prevention, early identification and optimal management of cutaneous reactions associated with EGFR inhibitor therapy.
Learning Outcomes:
- Understand the mechanism of action of how the EGFR inhibitor affects the structure and function of the skin
- Recognise and describe the various cutaneous reactions that occur in patients being treated with EGFR inhibitors
- Follow general management pathways for treating cutaneous reactions associated with EGFR inhibitor treatment
Presenter: Marc Diocera, Nurse Consultant, Peter MacCallum Cancer Centre
Description: TBC